{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-023265","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.750660+00:00","generated_at":"2026-05-18T23:23:43.857142+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program","bullets":["Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.","OPGx-MERTK targets retinitis pigmentosa caused by MERTK gene mutations; no approved therapies exist.","Funding expected to support IND-enabling studies and advance gene therapy pipeline for inherited retinal diseases.","Cash runway extended into second half of fiscal year 2026, based on current projections."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-023265","json":"https://secwatch.observer/filing/0001140361-25-023265.json","markdown":"https://secwatch.observer/filing/0001140361-25-023265.md","text":"https://secwatch.observer/filing/0001140361-25-023265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/0001140361-25-023265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/ef20050882_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:23:43.857142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}